Specification of Drug Substances and Products
Development and Validation of Analytical Methods
- Publisher's listprice EUR 195.00
-
76 167 Ft (72 540 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 7 617 Ft off)
- Discounted price 68 550 Ft (65 286 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
76 167 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 2
- Publisher Elsevier Science
- Date of Publication 24 July 2020
- ISBN 9780081028247
- Binding Paperback
- No. of pages694 pages
- Size 234x190 mm
- Weight 1540 g
- Language English 6
Categories
Long description:
Specification of Drug Substances and Products: Development and Validation of Analytical Methods, Second Edition, presents a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development, validation of analytical methods, and their application in practice. This thoroughly revised second edition covers topics not covered or not substantially covered in the first edition, including method development and validation in the clinical phase, method transfer, process analytical technology, analytical life cycle management, special challenges with generic drugs, genotoxic impurities, topical products, nasal sprays and inhalation products, and biotechnology products.
The book's authors have been carefully selected as former members of the ICH Expert Working Groups charged with developing the ICH guidelines, and/or subject-matter experts in the industry, academia and in government laboratories.
Table of Contents:
PART 1-INTRODUCTION
1.-Introduction
2.-General Principles and Regulatory Considerations: Specifications and Shelf Life Setting
3.-General Principles and Regulatory Considerations: Method Development and Validation
4.-Application of Quality by Design (QbD) to the Development and Validation of Analytical Methods
5.-Analytical Methods in the Clinical Phase of Development
6. Method Transfer
7. Process Analytical Technology
PART 2-UNIVERSAL TESTS
8.-Description and Identification
9. Assay and Impurities: Specifications
10.-Assay and Impurities: Method Development and Life-Cycle Management
11.-Assay and Impurities: Method Validation
12.-Mutagenic Impurities
13.-Residual Solvents
14.-Inorganic Impurities (Elemental Impurities)
PART 3-SPECIFIC TESTS: DRUG SUBSTANCES
15.-Solid State Characterization
16.-Chiral Methods
17.-Water Determination
PART 4-SPECIFIC TESTS DRUG PRODUCT
18.-Drug Release: Oral Products
19.-Topical Products
20.-Extractables and Leachables
PART 5-BIOTECHNOLOGY PRODUCTS
21. Regulatory Requirements for Setting Drug Substance and Drug Product Specifications-
22. Validation of Analytical Methods for Biotechnology Products
PART 6-PHARMACOPEIAL METHODS
23.-Pharmacopeial Methods and Test (Updated)
PART 7-BIOLOGICAL FLUIDS
24.-Biological Fluids
